Close mobile menu×
Close mobile menu

Bret Taback, MD

Board Certifications: 
Surgery
Expertise in: 
Breast Surgery, Sarcoma, Melanoma, Cancer Care, Breast Cancer
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-9676

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor

Board Certifications

  • Surgery

Clinical Expertise

  • Sarcoma
  • Melanoma
  • Cancer Care
  • Breast Surgery
  • Breast Cancer
  • Breast Cancer Surgery
  • Sentinel Node Biopsy For Breast
  • Mastectomies
  • Breast Disease
  • Specialist in Breast Cancer Surgery
  • Specialist in Melanoma Surgery

Specialties

Education & Training

  • Baystate Medical College - Tufts University School of Medicine
  • Residency: Brown University Rhode Island Hospital
  • Residency: Northwestern University Hospital
  • Fellowship: Beth Israel Deaconess Medical Center
  • Fellowship: John Wayne Cancer Institute , Santa Monica CA

Honors & Awards

  • Member, International Scientific Committee, The 4th International Sentinel Node Congress, Los Angeles, CA (2004)
  • Co-Chairman, The 3rd International Conference on Circulating Nucleic Acids in Plasma and Serum & Serum Proteomics (CNAPS III), Santa Monica, CA (2003)
  • Young Investigator Award, The 3rd International Sentinel Node Congress, Yokohama, Japan (2002)
  • Merit Award, American Society of Clinical Oncology, Orlando, FL (2002)
  • Elected to Associate Member Council, American Association for Cancer Research, Philadelphia, PA (2001-2004)
  • Scholarship Award to attend Epidemiology and Biostatistics Conference, Berlex Oncology Foundation, Hackensack, NJ (2001)
  • Joyce Eisenberg-Keefer Fellowship Award, Santa Monica, CA (2000)
  • Merit Award, American Society of Clinical Oncology, New Orleans, LA (2000)

About Bret Taback

Dr. Bret Taback is a nationally recognized surgical oncologist in the New York-Presbyterian/Columbia University Medical Center department of surgery. Dr. Taback is Assistant Professor of Surgery at the Columbia University Medical Center, and a leader in the clinical management of melanoma, sarcoma and skin/soft tissue tumor surgery. Dr. Taback is the Director of the Melanoma and Sarcoma Program and Director of the Breast Surgery Fellowship. Dr. Taback received his MD degree at Tufts University School of Medicine in Boston , and completed his general surgery residency at Brown University, Rhode Island Hospital. 

During that time he completed a Basic Science Research Fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston. Following this, he completed a fellowship in Complex Surgical Oncology at the John Wayne Cancer Institute, Santa Monica, California. Dr. Taback is a member of a number of organizations and societies including Society of Surgical Oncology, American Society of Clinical Oncology and the American Association for Cancer Research. He is also a Fellow of the American College of Surgeons. He has published and authored numerous peer review manuscripts, abstracts and presentations, as well as book chapters over the years in notable publications such as Annals of Surgery, Annals of Surgical Oncology, Cancer Research, Clinical Cancer Research and the Journal of the National Cancer Institute. He is a clinical investigator with SWOG and Alliance for clinical trials. Dr. Taback has served on numerous hospital committees including tumor boards, Institutional Review Boards, Oncology Operations Council and is the American College of Surgeon’s Commission on Cancer Physician Liaison for NYP Hospital. Most recently, Dr. Taback is a noted Castle Connolly Top Doctor.

Academic Titles

  • Assistant Professor of Surgery at CUMC

Administrative Positions

  • Director, Melanoma and Sarcoma
  • Director, Breast Surgery Fellowship

Committee/Societies/Council Memberships

  • American Board of Surgery
  • Diplomate of the National Board of Medical Examiners
  • American Society of General Surgeons
  • American Association for Cancer Research
  • American Association for the Advancement of Science
  • American College of Surgeons
  • American Medical Association
  • American Society for Investigative Pathology
  • American Society of Clinical Oncology
  • Association for Academic Surgery
  • Society for Surgical Oncology
  • Society of Laparoendoscopic Surgery

Hospital Affiliations

  • NewYork-Presbyterian/Columbia
  • NewYork-Presbyterian/Lawrence Hospital

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-9676
Fax:
(212) 305-1522
Primary

Research

Research Interests

  • Tumor genetics and profiling
  • Micrometastasis and minimal residual disease surveillance
  • Circulating nucleic acids in plasma and serum

Grants

A RANDOMIZED TRIAL EVALUATING BIOIMPEDANCE SPECTROSCOPY VERSUS TAPE MEASUREMENT IN THE PREVENTION OF LYMPHEDEMA FOLLOWING LOCOREGIONAL TREATMENT FOR BREAST CANCER (P&S Industry Clinical Trial)

Aug 12 2016 - Aug 12 2021

A REGISTRY STUDY TO EVALUATE THE SURVIVAL AND LONG TERM SAFETY OF SUBJECTS WHO PREVIOUSLY RECEIVED TALIMOGENE LAHERPAREPVEC (P&S Industry Clinical Trial)

Mar 4 2015 - Mar 4 2020

PROLEUKIN? OBSERVATIONAL REGISTRY TO EVALUATE THE TREATMENT PATTERNS AND CLINICAL RESPONSE IN MALIGNANCY (P&S Industry Clinical Trial)

Nov 12 2013 - Nov 12 2018

A MULTI-CENTER STUDY OF HIGH DOSE ALDESLEUKIN (INTERLEUKIN-2) + VEMURAFENIB THERAPY IN PATIENTS WITH BRAF V600 MUTATION POSITIVE METASTATIC MELANOMA (P&S Industry Clinical Trial)

Oct 8 2013 - Oct 8 2018

A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II TRIAL OF THE MEK INHIBITOR PIMASERTIB OR DACARBAZINE IN PREVIOUSLY UNTREATED SUBJECTS WITH N-RAS MUTATED LOCALLY ADVANCED OR METASTATIC MALIGNANT CUTANEOUS MELANOMA (P&S Industry Clinical Trial)

Feb 25 2013 - Feb 25 2018

AMERICAN COLLEGE OF SURGEONS ONCOLOGY GROUP (ACOSOG) U10 CA7 6001 (Federal Gov)

Aug 30 2006 - Aug 29 2016

RO5185426 (P&S Industry Clinical Trial)

Aug 12 2011 - Aug 12 2016

ONCOVEX 005/05: A RANDOMIZED PHASE 3 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH ONCOVEXGM (P&S Industry Clinical Trial)

Jul 15 2010 - Jul 15 2015

MULTICENTER SELECTIVE LYMPHADENECTOMY FOR MELANOMA TRIAL II: A PHASE III MULTICENTER RANDOMIZED TRIAL OF SENTINEL LYMPHADENECTOMY AND COMPLETE LYMPH NODE DISSECTION VERSUS SENTINEL LYMPHADENECTOMY ALO (Federal Gov)

Sep 27 2010 - Aug 31 2013

MULTICENTER SELECTIVE LYMPHADENECTOMY FOR MELANOMA TRIAL II: A PHASE III MULTICENTER RANDOMIZED TRIAL OF SENTINEL LYMPHA (Federal Gov)

Sep 27 2010 - Aug 31 2012

Selected Publications

  • Shinozaki M, Hoon D, Giuliano A, Hansen N, Wang H, Turner R, Taback B. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res. 11:2156-2162, 2005
  • Taback B, Hoon D. Advances in circulating nucleic acids and serum proteomics: synopsis of the 3rd International Conference. Clin Chem. 50:2230-2232, 2004
  • Taback B, Hoon D. Circulating nucleic acids in plasma and serum: past, present and future. Curr Opin Mol Ther. 6:273-278, 2004
  • Taback B, O'Day S, Hoon D. Quantification of circulating DNA in the plasma and serum of cancer patients. Ann NY Acad Sci. 1022:17-24, 2004
  • Taback B, Hoon D. Circulating nucleic acids and proteomics of plasma/serum: clinical utility. Ann NY Acad Sci. 1022:1-8, 2004
  • Taback B, Bilchik A, Saha S, Nakayama T, Wiese D, Turner R, Kuo C, Hoon D. Peptide nucleic acid clamp PCR: A novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer 111:409-414, 2004
  • Takeuchi H, Morton D, Kuo C, Turner R, Elashoff D, Elashoff R, Taback B, Fujimoto A, Hoon D. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol. 22:2671-2680, 2004
  • Fujimoto A, O'Day S, Taback B, Elashoff D, Hoon D. Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res. 64:4085-4088, 2004
  • Taback B, Hoon. Microsatellite alterations as diagnostic and prognostic molecular markers in patients with cancer. In: R.M. Nakamura, W. Grody, J. Wu, R. Nagle (eds), Cancer Diagnostics: Current and Future Trends. Humana Press, Inc., Totowa, New Jersey, 2004; 19:395-428
  • Hoon D, Spugnardi M, Kuo C, Huang S, Morton D, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene. 23:4014-4022, 2004
  • Fujimoto A, Takeuchi H, Taback B, Hsueh E, Elashoff D, Morton D, Hoon D. Allelic imbalance of 12q22–23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res. 64:2245-2250, 2004
  • Takeuchi H, Taback B, Kuo C, Hoon D. Clinicopathological utility of molecular staging for melanoma patients undergoing sentinel lymphadenectomy.
  • Ann Surg Oncol. 11(3 Suppl):152S-5S, 2004
  • Taback B, O'Day S, Boasberg P, Shu S, Fournier P, Elashoff R, Wang H, Hoon D. Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst. 96:152-156, 2004
  • Kuo C, Hoon D, Takeuchi H, Turner R, Wang H, Morton D, Taback B. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol. 21: 3566-3572, 2003
  • Taback B, Hoon D. Ultrastaging of Melanoma Patients: Molecular Detection of Micrometastatic Disease. In: J.F. Thompson, D.L. Morton, and B.R. Kroon (eds.), Melanoma. Martin Dunitz 2004; 13:148-163
  • Taback B, Giuliano A, Hansen N, Singer F, Shu S, Hoon D. Detection of tumor-specific genetic alterations in bone marrow from early stage breast cancer patients. Cancer Res. 63: 1884-1887, 2003
  • Hoon D, Fujimoto A, Shu S, Taback B. Assessment of genetic heterogeneity in tumors using laser capture microdissection. Methods Enzymol. 356:302-309, 2002
  • Taback B, Hashimoto K, Kuo CT, Chan A, Giuliano AE, Hoon D. Molecular lymphatic mapping of the sentinel lymph node. Am J Pathol. 161: 1153-1161, 2002
  • Taback B, Chan AD, Kuo CT, Bostick P, Wang H, Giuliano AE, Hoon D. Detection of occult metastatic breast cancer cells in blood by a multi-molecular marker assay: correlation with clinical stage of disease. Cancer Res. 61: 8845-8850, 2001
  • Taback B, Giuliano A, Hansen N, Hoon D. Microsatellite alterations detected in the serum of early stage breast cancer patients. In: P. Anker and M. Stroun (eds.), Circulating Nucleic Acids in Plasma or Serum II. Ann NY Acad Sci. 945: 22-30, 2001
Abstracts
  • Taback B, Nguyen P, Hansen N, Edwards K, Conway K, Giuliano A. Sentinel lymph node biopsy for patients with local breast cancer recurrence following breast-conserving surgery and adjuvant radiotherapy. Ann Surg Oncol. 12(2 Suppl): S66, 2005
  • Taback B, Hansen N, Conway K, Giuliano A. Recurrence patterns following a negative sentinel lymph node biopsy in patients with early-stage breast cancer. Proceedings of the American Society of Clinical Oncology 23: 560a, 2004
  • Taback B, Lai R, Giuliano A, Singer F, Hansen N, Hoon, D. Identification of tumor-associated epigenetic alterations in bone marrow and serum from early-stage breast cancer patients using a hypermethylation gene panel. Proceedings of the American Association for Cancer Research 45: 772, 2004
  • Taback B, Lai R, Giuliano A, Singer F, Hansen N, Hoon D. Detection of tumor-related epigenetic alterations in bone marrow from early-stage breast cancer patients using a hypermethylation gene panel. Journal of Bone and Mineral Research 19: 1578, 2004
  • Taback B, Hoon D. Quantitation of DNA in the serum and plasma of cancer patients. Clinical Chemistry 49: 3, 2003
  • Kuo C, Spugnardi M, Taback B, Hoon D. Epigenetic inactivation of tumor suppressor genes in paired plasma and tumors from cutaneous melanoma patients. Clinical Chemistry 49: 5, 2003
  • O'Day S, Fujimoto A, Taback B, Elashoff D, Hoon D. Allelic imbalance on 12q22-23 locus in serum DNA of melanoma patients predicts response to biochemotherapy. Clinical Chemistry 49: 7, 2003
  • Taback B, Kuo C, Takeuchi H, Turner R, Wang H, Morton, D, Hoon D. Molecular analysis of melanoma patients paraffin-embedded sentinel lymph nodes predicts disease outcome. Proceedings of the American Society of Clinical Oncology 22: 713, 2003
  • Taback B, Giuliano A, Hansen N, Singer R, Hoon D. Identification of tumor-specific genetic alterations in the bone marrow of early stage breast cancer patients. Proceedings of the American Association for Cancer Research 44: 563, 2003
  • Shinozaki M, Giuliano A, Taback B, Hoon D. CpG hypermethylation of the glutathione S-transferase P1 and retinoic acid receptor-β genes in primary breast cancer correlates with lymph node metastasis. Proceedings of the American Association for Cancer Research 44: 1233, 2003
  • Fujimoto A, Takeuchi H, Shu S, Hsueh E, Taback B, Hoon D. Prognostic significance of LOH of the APAF-1 locus in malignant melanoma. Proceedings of the American Association for Cancer Research 44: 1080, 2003
  • Taback B, Shu S, Hansen N, Giuliano A, Hoon D. Detection of tumor-specific DNA in breast cancer patients' sera. Department of Defense Era of Hope Proceedings, Vol II: P24-7, 2002
  • Taback B, O'Day S, Fournier P, Hoon D. Serum genetic markers as surrogates of response to biochemotherapy in patients with metastatic melanoma. Proceedings of the American Society of Clinical Oncology 21: 339a, 2002
  • Taback B, Nakayama T, Wiese D, Turner R, Bilchik A, Saha S, Hoon D. Detection of colorectal micrometastasis in sentinel lymph nodes using the novel approach of PCR PNA clamping. Proceedings of the American Association for Cancer Research. 42: 612, 2001
  • Taback B, Giuliano AE, Hansen N, Hoon D. Circulating DNA microsatellites with LOH in early stage breast cancer patients serum is associated with increased tumor proliferation. Clinical Chemistry, 47: 365, 2001
  • Hoon D, Taback B, Morton DL, Fujiwara Y. DNA microsatellite markers with LOH in plasma from stage III melanoma patients is associated with a decreased survival. Clinical Chemistry, 47: 363, 2001
  • Taback B, Nakayama T, Turner, R, Morton, D, Hoon, D. Genetic clonality of primary melanoma and subsequent in-transit metastases. Melanoma Research, 11(Supp 1): S206, 2001
  • Taback B, Morton D, Fujiwara Y, O’Day S, Fournier P, Hoon, D. Circulating DNA microsatellite markers is associated with a poorer prognosis in high-risk melanoma patients undergoing therapeutic interventions. Melanoma Research, 11(Suppl 1): S75, 2001
  • Taback B, Chan A, Kuo C, Nguyen D, Giuliano A, Hoon D. Molecular detection of metastatic cells in the blood of breast cancer patients. Department of Defense Era of Hope Proceedings, Vol I: 121, 2000
  • Taback B, Giuliano AE, Nguyen D, Nakayama T, Hansen N, Martino S, Fournier PJ, Hoon D. Tumor-related free DNA microsatellites detected in breast cancer patients serum correlates with disease progression. Proceedings of the American Society of Clinical Oncology19: 606a, 2000